Parkman Healthcare Partners LLC boosted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 207.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,780,454 shares of the company's stock after buying an additional 1,201,943 shares during the quarter. Parkman Healthcare Partners LLC owned about 1.14% of Xeris Biopharma worth $9,775,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new stake in Xeris Biopharma during the fourth quarter worth approximately $45,000. Two Sigma Advisers LP bought a new position in Xeris Biopharma during the fourth quarter valued at about $47,000. Apella Capital LLC acquired a new position in shares of Xeris Biopharma in the first quarter valued at $55,000. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Xeris Biopharma by 31.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company's stock worth $55,000 after acquiring an additional 3,847 shares during the period. Finally, Xponance Inc. bought a new position in Xeris Biopharma during the first quarter worth about $57,000. Institutional investors and hedge funds own 42.75% of the company's stock.
Xeris Biopharma Trading Down 1.8%
Shares of Xeris Biopharma stock traded down $0.14 during midday trading on Thursday, reaching $7.67. The company had a trading volume of 1,262,811 shares, compared to its average volume of 2,510,803. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -36.52 and a beta of 0.13. Xeris Biopharma Holdings, Inc. has a 1-year low of $2.69 and a 1-year high of $8.03. The stock has a fifty day simple moving average of $6.37 and a 200 day simple moving average of $5.22.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.02. The firm had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million. Sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages have weighed in on XERS. Wall Street Zen cut Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. HC Wainwright initiated coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They set a "buy" rating and a $10.00 price target for the company. Finally, Leerink Partners upped their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 19th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Xeris Biopharma has an average rating of "Moderate Buy" and an average price target of $7.08.
Read Our Latest Research Report on XERS
Insider Buying and Selling at Xeris Biopharma
In related news, Director John Johnson sold 107,500 shares of the company's stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total value of $786,900.00. Following the completion of the sale, the director owned 833,483 shares in the company, valued at approximately $6,101,095.56. This represents a 11.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Dawn Halkuff sold 42,500 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $7.28, for a total value of $309,400.00. Following the completion of the transaction, the director directly owned 115,000 shares in the company, valued at $837,200. The trade was a 26.98% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 192,232 shares of company stock worth $1,430,777 over the last quarter. 6.47% of the stock is currently owned by insiders.
Xeris Biopharma Profile
(
Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
See Also
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
